Pharmaceutical marketing just got a shake-up. Solstice, a New York startup, raised $21 million in Series A funding to slash approval times for drug marketing materials. The company targets a painfully slow process called MLR review—medical, legal, and regulatory checks that stall marketing assets for months. Solstice’s platform combines AI with in-house experts to compress












